As former Chief Scientific Officer of Johnson & Johnson, Paul Stoffels spearheaded its research and product pipeline by leading teams across all sectors to set the companywide innovation agenda, discovering and developing transformational healthcare solutions. He also was responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steered the company’s global public health strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings.

In 2002, he joined Johnson & Johnson with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of several breakthrough products for the treatment of HIV, which helped to transform this devastating disease from a death sentence to a chronic and treatable condition. Dr. Stoffels retired from his post at Johnson & Johnson in 2021.

Dr. Stoffels studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.